ImmunityBio, Inc. (IBRX)

NMS – Real Time Price. Currency in USD

8.12

+0.01 (0.12%)

At close: May 12, 2026, 4:00 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

113M

15M

622K

240K

Cost of goods sold

-16M

-18M

-19M

-24M

Gross Profit

97M

-3M

-18M

-24M

Operating expenses (excl. COGS)

-353M

-341M

-343M

-327M

Operating Income

-256M

-344M

-361M

-351M

Non-operating income, total

-96M

-69M

-223M

-67M

Pretax income

-352M

-414M

-584M

-417M

Equity in earnings

Taxes

135K

40K

-34K

Non-controlling/minority interest

74K

81K

656K

753K

After tax other income/expense

Net income before discontinued operations

-351M

-414M

-583M

-417M

ImmunityBio, Inc. (IBRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ImmunityBio, Inc. (IBRX)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

ImmunityBio, Inc. (IBRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ImmunityBio, Inc. (IBRX)

Income Statement (Annual)

Income Statement (Annual)